Pharmaceuticals - , ,
Exegiline is developing a novel oral drug, MT-31, for the treatment of the symptoms related to Alzheimer's Disease. MT-31 structure combines Rivastigmine (Exelon) with Rasagiline's (Azilect) propargyl moiety having unique beneficial properties. MT-31, its derivatives and indication, are protected by a recently granted US and EP patents.
Google AdSense
Google Cloud Hosting
Mobile Friendly